DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/sb5wl6/chinas_2013_life) has announced the addition of the "China's 2013 Life Sciences Industry Outlook and Regulatory Review" report to their offering.
Government Investments Could Make China the Third-largest Pharmaceutical Market in the World
China is predicted to become the third-largest pharmaceutical market in the world by the end of 2013 due to the government's considerable investment in the healthcare industry and the population's unmet healthcare needs. The life sciences industry is broad and involves a wide range of disciplines.
This research service focuses on the trends and market opportunities in China's life sciences industry - the regulatory environment, the registration pathway of various drugs and IVD products, and M&A. Medical devices and the related registration pathway are not included. In this study, the base year is 2012, and the forecast period runs 2013-2017. An analysis of market challenges, drivers, and restraints impacting industry growth are provided.
Examples of Key Findings
The aging population and the development of what are know as Western diseases, such as type 2 diabetes, cardiovascular diseases, breast cancer, allergies, and mental health problems are positioned to drive medical needs. The new drugs expected to hit the Chinese market will address these needs.
The State Food and Drug Administration (SFDA) is adopting more stringent requirements for the registration of drugs and in vitro diagnostics (IVD), leading to increasing efforts by companies to focus on manufacturing high-quality products. To narrow the drug quality gap and align with international standards, the SFDA will strengthen its supervision of the safety and quality of healthcare products.
With the ongoing reform of public hospitals and the ensuring drug pricing mechanism, IVD testing revenue is likely to account for an increasing proportion of a hospital's income.
Integration, optimization of distribution channels, and cost reduction are major factors encouraging domestic participants and multinational corporations (MNCs) to engage in merger and acquisitions (M&A) activities. Domestic M&A surge as Chinese pharmaceutical companies lead a new wave of consolidation.
Key Topics Covered
- Executive Summary
- China's Regulatory Pathway for Drugs and IVD
- China's Regulatory Trends and Market Outlook
- External Challenges: Drivers and Restraints
- Forecasts and Trends
- Leading Life Sciences Companies to Watch in China
- M&A Activities
- Conclusions
- Appendix
For more information visit http://www.researchandmarkets.com/research/sb5wl6/chinas_2013_life.
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
